Guardant Health Rocks ASCO!

Our client, Guardant Health, recently attended the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. As we mentioned in our previous blog, Guardant Health is a growing healthcare company focused on the development and commercialization of oncology diagnostic products.

While at ASCO, Guardant Health participated in poster sessions and announced the U.S. commercial launch of their premier product, Guardant360. Hard tumor biopsies are not always available from patients due to risk or lack of tissue. Guardant360 is a simple blood test that identifies a patient's genomic alterations through patented sequencing of cell free DNA, which can be used to assist in directing a patient’s personalized therapy plan.

Helmy Eltoukhy, Ph.D., Guardant Health’s co-founder and CEO said, “As a simple blood test, it provides physicians with a streamlined, cost-effective method to identify genomic alterations that can comprehensively influence a patient’s therapy response.”

For more information, view the ASCO Guardant360 posters.


Erin LaFavor